Navigation Links
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
Date:10/29/2009

loan from Bay City Capital;
  • our ability to timely recruit and enroll patients in any future clinical trials;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiometabolic clinical trials using surrogate endpoints in Phase 1 and Phase 2 clinical trials which may differ from the ultimate endpoints required for registration of a candidate drug;
  • the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291;
  • if the results of the ACS and CEA studies, upon further review and analysis, are revised, interpreted differently by regulatory authorities or negated by later stage clinical trials;
  • our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291;
  • our ability to successfully commercialize VIA-2291;
  • our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development;
  • our ability to obtain and protect our intellectual property related to our product candidates;
  • our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche;
  • our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291;
  • our ability to form and maintain collaborative relationships to develop and commercialize our product candidates;
  • general economic and business conditions; and
  • the other risks described under Item 1A "Risk
    '/>"/>

  • SOURCE VIA Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine news :

    1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
    2. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
    3. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
    4. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
    5. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
    6. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
    7. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
    8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
    9. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
    10. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
    11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... In his latest blog post at ... facility CEO Per Wickstrom has listed 5 ways to ... confirm an appointment, get information or sometimes even just ... being annoying is a skill that most people don’t ... to keep the dialogue moving without coming across as ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
    (Date:7/10/2014)... City, CA (PRWEB) July 10, 2014 ... announced the latest results of the 4th “Trending ... "Source-to-Pay” suite model. , Every day multinational ... data, contracts, expense forms etc. To meet this ... "Source-to-Pay" (S2P) suites which can be defined as ...
    (Date:7/10/2014)... widespread across the United States, due in large to ... of clinical data that will become available for research ... experts in healthcare have become increasingly focused on clinical ... purpose of gleaning insights that have the potential to ... that is known as big data. ...
    (Date:7/10/2014)... professional football players who have shoulder stabilization surgery are ... finds. Shoulder instability is a common injury among ... to fix the problem has been unclear, the study ... who had shoulder stabilization surgery. Ninety percent of those ... as playing in at least one regular season game. ...
    Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
    ... came to the Brampton, Ont., Tim Horton's location are being ... ,According to health officials in Peel Region, an employee ... tested positive for hepatitis A. ,Peel's associate medical ... that the risk of transmission is low. ,However De Villa ...
    ... Egger, of the University of Bern in Switzerland, AIDS ... side effects// due the drug. ,There is ... It been ten years since the antiretroviral (ARVs) have ... and drawbacks. Scientists say that the combinations of drugs ...
    ... fibers could stretch to three times its length before going ... to six times// their original length before breaking. ... from a soluble protein, fibrinogen. When an injury occurs ... a mesh, which dries and hardens, so that bleeding stops. ...
    ... been a storm brewing over a particular brand of milk, ... on the warfarin drug. Fonterra, the company// that is manufacturing ... were well aware of the impending risks of the milk ... to disclose the warning on the product. ...
    ... who was denied admission to a medical college here because ... disability, has urged President// A.P.J. Abdul Kalam to intervene. ... of the state joint entrance examination, was denied admission to ... examining her again despite the chief district medical officer R.C. ...
    ... popular supermarket chains have announced that they would completely avoid ... ,Trans fat was recently in the news as it increased ... thought to cause cancers among some people. The supermarket chains ... amounts of hydrogenated oil pose great threat and affected the ...
    Cached Medicine News:
    (Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
    (Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
    (Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
    Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
    ... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... its strategic advisor as it pursues various avenues aimed at ... ANA598, in development for the treatment of hepatitis C.  Anadys ... conclusion of 12 weeks of dosing ANA598 in combination with ...
    ... Inc. (OTC Bulletin Board: HEWA), a leading retail mail-order ... (VIPPS(CM)) accreditation from The National Association of Boards of Pharmacy (NABP). ... accredited in the United States .   , ... According to NABP which has ...
    Cached Medicine Technology:Anadys Retains Lazard as Strategic Advisor 2Anadys Retains Lazard as Strategic Advisor 3Anadys Retains Lazard as Strategic Advisor 4Anadys Retains Lazard as Strategic Advisor 5HealthWarehouse.com Receives VIPPS Accreditation From The National Association of Boards of Pharmacy 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: